Dr. Colón brings over 25 years’ experience in biopharma, genomics, healthcare and industrial biotechnology. She is currently CEO of InCarda Therapeutics, where she has raised nearly $50M to take the company’s lead program from early pre-clinical through its current stage in Phase 2. She is also executive chair of ProterixBio and board director at CareDx (NASDAQ:CDNA) and Cocoon Biotech. She is also a member of the Advisory Board of the Miller Center for Social Entrepreneurship at Santa Clara University. She was formerly a partner at New Science Ventures and served on the board of directors of Paradigm Diagnostics and PerceptiMed. Previously, she was founding President of the Industrial Products Division at Intrexon Corporation, where she established a new division using synthetic biology for biofuels and renewable chemicals. Prior to Intrexon, she held various leadership roles at Gilead Sciences, including heading up the commercial strategic planning, alliance management, and global clinical operations groups. Prior to Gilead, she was VP, Corporate Planning at Affymetrix, where she also served as COO for the International Genomics Consortium, a non-profit medical research organization focused on cancer genomics. Earlier in her career she was a consultant with McKinsey & Co., where she served clients in healthcare, biotech, high tech and venture capital. She was also an engineer with Merck & Co. in France and in Rahway, NJ. Dr. Colón received her Ph.D. from the Massachusetts Institute of Technology and a B.S. degree from the University of Pennsylvania, both in chemical engineering.
While most of the attention in the use of digital health for chronic care management has gone to…